Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Neoplasms of the Prostate Patients must have documented histological or cytological evidence of tumor(s) of the prostate Patients must be ≥ 45 years of age Patients or their legal representative must be able to read, understand and sign an informed consent Organ confined clinical T1C or clinical T2a prostate cancer that is visualized on MR imaging Prostate cancer is diagnosed by MR image guided biopsies Gleason Score ≤ 7; and 2 or less positive lesions on prior MR US fusion guided prostate biopsy A non MRI visible cancer detected via systematic standard biopsy will not be considered an condition provided the non-MRI visible cancer is singularly located in the contralateral hemisphere of the prostate; is Gleason 6 cancer; and comprises no more than 6mm linear extent of cancer in a single core on standard biopsy If any standard biopsy cores are positive on the same hemisphere of the prostate gland, they must be confirmed as likely to form a contiguous lesion with the target lesion detected on MRI and therefore be from the same location in the prostate as MR lesion was biopsied and proven to be cancerous. (e.g., Left/Right, Base, Mid Gland, Apex) Prior mpMRI results dated within 120 days prior to ablation No metastatic disease as per NCCN guidelines (www.nccn.org)  Patients with known hypersensitivity to any of the components of the PEGylated AuroShell suspension (polyethylene glycol, gold) Patients who are receiving concurrent investigational therapy or who have received investigational therapy within a period of 5 half-lives of the investigational therapy in questions prior to the day of dosing with PEGylated AuroShell particles (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication) Patients with evidence of an active bacterial infection or with a fever ≥ 38.5 ºC (101.3 ºF) within 3 days of the first scheduled day of dosing Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results The presence of 3 or more MR Visible lesions positive on biopsy The presence of extra capsular, seminal vesicle invasion or metastatic disease Patient is unable to tolerate MRI (foreign body; i.e. pacemaker or other implanted device; claustrophobia; inability to tolerate rectal coil, etc.…) Patient with inability to follow up History of prior treatment for prostate cancer Acute urinary tract infection